NR3C2 and type 2 diabetes mellitus: Most recently, the large Phase III FIDELIO-DKD trial reported that, in patients with chronic kidney disease (CKD) and type 2 diabetes, MR antagonism reduced the risk of CKD progression, albuminuria, and cardiovascular events (13).